Hospira’s contract manufacturing service will supply clinical and commercial quantities on a worldwide basis.
Hospira Worldwide will supply Durect with its Phase II post-surgical pain management drug, Posidur ™. According to the long-term manufacturing and supply agreement, Hospira’s One 2 One® contract manufacturing services will provide clinical and commercial supplies on a worldwide basis.
“Hospira’s capabilities, expertise and capacity in manufacturing parenteral products makes them an ideal partner for us,” says James Brown, CEO of DURECT. “The establishment of this agreement, following on the heels of our recent development and commercialization collaboration with Nycomed, now one of the 25 largest pharmaceutical companies in the world as a result of its Altana acquisition, is a second key milestone in our POSIDUR development program.”
Posidur is intended to be injected during surgery, where it continuously releases therapeutic levels of bupivacaine in a controlled fashion, providing up to 72 hours of uninterrupted local analgesia, according to Durect.